Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19 T Cells with Cytoplasmic PD-1 in B-Cell Lymphoma
NCT03540303Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR19 T cells carrying cytoplasmic activated PD-1 in B-cell non-Hodgkin lymphoma, sponsored by Henan Cancer Hospital. Primary endpoint: Occurrence of study related adverse events at 6 months. Status: unknown.
02
Drugs
CAR19 T cells carrying cytoplasmic activated PD-1
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03540303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540303.